Amber Bio
A biotechnology company developing a first-of-its-kind RNA writing platform using multi-kilobase edits to reach previously undruggable patient populations, pioneering new gene editing modalities for genetic medicine.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
* | $26.0m | Seed | |
| Total Funding | 000k | ||
Related Content
Amber Bio is a biotechnology company that has developed a platform for RNA editing. This platform allows for the editing of multi-kilobase RNA strands, which can be used to correct genetic mutations that cause diseases.
The company's technology is based on a deep understanding of RNA biology and machine learning. Amber Bio's platform has the potential to treat a wide range of diseases, including genetic disorders, cancer, and infectious diseases.
Amber Bio was founded in 2023 by a team of experienced scientists and entrepreneurs. The company has raised $26 million in seed financing from Playground Global and Andreessen Horowitz.
Keywords: RNA editing, gene therapy, biotechnology, genetic disorders, cancer, infectious diseases, machine learning, drug development, therapeutics, platform